Coya Therapeutics (COYA) Cash from Operations Growth (1y) (2023 - 2026)
Coya Therapeutics (COYA) Cash from Operations Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 158.60% |
| 10 | Coya Therapeutics | 97.37 Mn | 46.65 Mn | - | -119.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.52% |
| Dec 31, 2025 | 58.21% |
| Sep 30, 2025 | 79.30% |
| Jun 30, 2025 | -26.51% |
| Mar 31, 2025 | -231.80% |
| Dec 31, 2024 | -7.53% |
| Sep 30, 2024 | -146.44% |
| Jun 30, 2024 | -59.13% |
| Mar 31, 2024 | 155.54% |
| Dec 31, 2023 | -0.81% |
| Sep 30, 2023 | -39.24% |
| Jun 30, 2023 | -99.15% |
| Mar 31, 2023 | -94.68% |